Ann: Sirtex Records Underlying Full Year NPAT of $42.4 Million, page-27

Jeff2046.

There was nothing in the result today that we didn't already know after the latest update was given on the 26th June.

The only negative was Andrew McLean the new CEO not wanting to give a dose sales forecast or answer the UBS analyst who asked about sales for the first 6 weeks of trading.

Who could blame Sirtex management from giving a forecast this early. Let's wait until the AGM in November.

The one thing I was surprised to learn was that there will be expenditure reductions now that the big studies are out of the way.

The sexiness has come out of the stock with the new CEO embarking on a course of maximising sales, streamlining expenses and only investing in studies likely to give a return. This sounds like he wants to run Sirtex to make a good return for ahareholders though it may take some time.